Inflammatory biotech InflaRx sets terms for $100 million IPO
InflaRx, which is developing antibodies for rare autoimmune and inflammatory diseases, announced terms for its IPO on Monday.
The Jena, Germany-based company plans to raise $100 million by offering 6.67 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering (40%). At the midpoint of the proposed range, InflaRx would command a fully diluted market value of $362 million.
InflaRx was founded in 2007 and plans to list on the Nasdaq under the symbol IFRX. J.P. Morgan, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of November 6, 2017.
The article Inflammatory biotech InflaRx sets terms for $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.